Mitchel Ibach
Optometrist · Sioux Falls, SDNPI 1184934069
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (45.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 28.1% of the total. 2025 is the largest year on record at $125,663, 6.8 times the $18,351 reported in 2019. Among optometrist clinicians in SD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 760 payments — averaging $519.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$111K
- Glaukos Corporation$109K
- Alcon$48K
- Dompe US, Inc.$22K
- Oyster Point Pharma, Inc.$19K
- Aerie Pharmaceuticals, Inc.$18K
- plus $67K from 24 others
Across 11 payments — averaging $32,154 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$354K
- AbbVie$109
What the payments were for
- Consulting fees$157,63040%
- Speaking & faculty fees$179,23345%
- Travel & lodging$40,64310%
- Food & beverage$17,5564%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 153 | $111,125 |
| Glaukos Corporation | 118 | $109,195 |
| Alcon | 114 | $48,117 |
| Dompe US, Inc. | 40 | $22,038 |
| Oyster Point Pharma, Inc. | 43 | $18,827 |
| Aerie Pharmaceuticals, Inc. | 41 | $18,423 |
| Sight Sciences, Inc. | 27 | $13,458 |
| Sun Pharmaceutical Industries Inc. | 33 | $10,051 |
| Alcon Research LLC | 13 | $9,777 |
| AbbVie(2 entities) | 44 | $8,847 |
| Thea Pharma Inc. | 17 | $8,039 |
| Heru, Inc. | 5 | $5,000 |
| Reichert, Inc. | 1 | $2,700 |
| Carl Zeiss Meditec, Inc. | 13 | $2,325 |
| NEW World Medical,inc. | 1 | $1,500 |
| Tarsus Pharmaceuticals, Inc. | 14 | $1,157 |
| Kala Pharmaceuticals, Inc. | 5 | $1,111 |
| Carl Zeiss Meditec USA, Inc. | 8 | $859 |
| Ocular Therapeutix, Inc. | 11 | $742 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $586 |
| Novartis | 19 | $396 |
| Mallinckrodt Hospital Products Inc. | 7 | $258 |
| Biotissue Holdings Inc. | 5 | $165 |
| Amgen(2 entities) | 6 | $125 |
| Shire North American Group Inc | 6 | $111 |
| Harrow Eye, LLC | 5 | $106 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $70 |
| Rxsight Inc | 1 | $30 |
| Tearlab Corp | 1 | $20 |
| The Cameron-ehlen Group, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MIEBO$107,293
- XIIDRA$100,766
- Rocklatan$46,627
- Rhopressa$45,982
- KXL System$36,536
- TYRVAYA$16,972
- TRYPTYR$16,620
- SIMBRINZA$13,050
- CE-marked KXLA system$12,529
- CEQUA$9,438
- ILINK$8,400
- OMNI$8,125
- Heru HMD$5,000
- OMNI(R) SURGICAL SYSTEM (US)$4,875
- Oxervate$3,735
- INFUSE$3,269
- IYUZEH$3,152
- VUITY$3,112
- iStent inject Trabecular Micro-Bypass Stent System$3,000
- iStent inject W$2,448
How this compares
$395,178 in reported general payments places this provider in the 95th percentile of 206 optometrist providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 17 | $452,558 |
| RestasisCyclosporine | 73 | $65,100 |
| VyzultaLatanoprostene Bunod | 142 | $52,041 |
| XiidraLifitegrast | 59 | $49,409 |
| RocklatanNetarsudil Mesylat/Latanoprost | 136 | $46,839 |
| XdemvyLotilaner | 25 | $45,780 |
| LumiganBimatoprost | 93 | $32,540 |
| CombiganBrimonidine Tartrate/Timolol | 84 | $18,862 |
| RhopressaNetarsudil Mesylate | 54 | $17,949 |
| Prednisolone Acetate | 341 | $11,695 |
| CequaCyclosporine | 16 | $10,641 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 42 | $8,239 |
| IyuzehLatanoprost/Pf | 18 | $7,017 |
| MoxifloxacinMoxifloxacin Hcl | 247 | $5,981 |
| Lotemax SmLoteprednol Etabonate | 18 | $4,490 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $22,038 | $452,55817 claims |
| AbbVieRestasis, Lumigan, Combigan | $8,847 | $116,502250 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $111,125 | $101,450201 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $18,423 | $64,788190 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $1,157 | $45,78025 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $10,051 | $10,64116 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa | $586 | $8,28329 claims |
| AlconSimbrinza | $48,117 | $8,23942 claims |
| Thea Pharma Inc.Iyuzeh | $8,039 | $7,01718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 206 optometrist providers in South Dakota.
Other optometrist in Sioux Falls
- Justin SchweitzerSioux Falls$753K
- Jason SchmitSioux Falls$79K
- Jeffery SaylerSioux Falls$8K
- Kayla KarpukSioux Falls$6K
- Travis LehrSioux Falls$5K
- Matthew ClarkeSioux Falls$5K
- Ryan HaiarSioux Falls$4K
- Kristen KramlichSioux Falls$4K
- Joshua TimsSioux Falls$4K
- Larae ZimprichSioux Falls$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.